Trial delays, lack of financing, Mono is still more than 1 year away from completed trials, combo therapy more than 1 year away from approval, no Tutes ownership .... it makes sense that we’re less than 200 Mill mkt cap. Much can change once the Prostagene deal is signed and prognostic test is approved / licensed